Published in AIDS Weekly, April 22nd, 1996
NeXstar plans to launch DaunoXome shortly at a price competitive with conventional therapy.
DaunoXome is formulated to maximize the selectivity of daunorubicin for solid tumors in the body. In granting approval for DaunoXome, the FDA noted that the drug was as effective as the current three-drug regimen of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.